The mechanism of action in schizophrenia and acute manic or mixed episodes of bipolar I disorder is unknown. Clinical efficacy may be mediated through a combination of dopamine D2 and serotonin 5-HT2 receptor antagonism. Milsaperidone and iloperidone rapidly interconvert in vivo; the receptor-binding profile is similar to iloperidone.
Indications / reported uses
Treatment of schizophrenia in adults under the US BYSANTI indication (initial US approval 2026)
Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults under the US BYSANTI indication; do not infer a distinct mechanism from its pharmacodynamic binding profile
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Milsaperidone Environmental Risk Assessment (ERA) (the Milsaperidone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.